Current Treatment Options with Immunoglobulin G for Adult Patients with Primary Immunodeficiency Disease in Poland

• Autorzy: Ewa Więsik-Szewczyk , Karin Jahnz-Różyk , Aleksandra Kucharczyk
• Języki publikacji: EN

Abstrakty

EN

Polyclonal immunoglobulin G life-long replacement is a corner stone therapy in patients with primary antibodies deficiency. The evidence of safety and effectiveness of IgG in PAD are strongly documented for reduction and protection for serious infections. There are still limited data for deletion from long term complications as progression of chronic lung diseases, bronchiectasis and damage. Nowadays accelerated progress in IgG products modulation and ways of administration allows for adjustment of this chronic treatment for patients needs and preferences, improving the patients' compliances and quality of life. Intra venous immunoglobulin therapy has been used for many years. There are worldwide accumulating experiences with subcutaneous therapy. The latter can be given by infusion delivery pump, via rapid push or facilitated by preinfusion of recombinant human hyaluronidase (rHuPH20). The immunoglobulin G life-long replacement is an expensive procedure. In the past in Poland replacement immunoglobulin therapy was provided mainly by pediatricians resulting in a gap with high quality care for adult patients. Awareness of problem of primary immunodeficiency in adult patients provokes the rise of centers which take care of adult patients. To improve the access for immunoglobulin therapy in Poland, a drug program has been introduced for adult patients with primary immunodeficiency. This review paper presents aspects of current immunoglobulin therapy in primary immunodeficiency complying resolutions proposed in Polish health care system(original abstract)

Słowa kluczowe

EN

Medications; Medical treatment; Health care

PL

Leki; Leczenie; Opieka zdrowotna

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2014
• Numer: nr 2
• Strony: 42--49

Twórcy

autor

Ewa Więsik-Szewczyk

• Military Institute of Medicine in Warsaw, Central Clinical Hospital of the Ministry of National Defense

autor

Karin Jahnz-Różyk

• Military Institute of Medicine in Warsaw, Central Clinical Hospital of the Ministry of National Defense

autor

Aleksandra Kucharczyk

• Military Institute of Medicine in Warsaw, Central Clinical Hospital of the Ministry of National Defense

Bibliografia

• Bruton OC.: Agammaglobulinemia. Pediatrics 1952; 9: 722-728
• Yong PL., Boyle J., Ballow M., et al.: Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin. Immunol. 2010; 135: 255-263
• Roifman CM., Berger M., Notarangelo LD.: Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol. Allergy. Clin. North. Am. 2008; 28: 875-876
• Available from: http://www.ivig.nhs.uk/documents/dh; [Accessed: 28.01.2015]
• Jolles S., Orange JS., Gardulf A., et al.: Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin. Exp. Immunol. 2015; 179:146-160
• Bousfiha AA., Jeddane L., Ailal F., et al.: Primary immunodeficiency diseases worldwide: more common than generally thought. J. Clin. Immunol. 2013; 33: 1-7
• Resnick ES., Moshier EL., Godbold JH., Cunningham-Rundles C.: Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119: 1650-1657
• Chapel H., Lucas M., Lee M., et al.: Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277-286
• Quinti I., Soresina A., Spadaro G., et al.: Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27: 308-316
• Quinti I., Agostini C., Tabolli S. et al.: Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood. 2012; 120: 1953-1954
• Gelfand EW., Ochs HD., Shearer WT.: Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J. Allergy. Clin. Immunol. 2013; 131: 1001-1005
• Piątosa B.: Flow cytometry as a reliable tool in diagnostics - review of basic principles, standard procedures and tests in diagnostics of primary immunodeficiencies. Central Eur. J. Immunol. 2007; 32, 247-257
• Gathmann B., Mahlaoui N., CEREDIH., et al.: Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J. Allergy. Clin. Immunol. 2014; 134: 116-126
• Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm078526.pdf; [Accessed: 30.01.2015]
• Busse PJ., Razvi S., Cunningham-Rundles C.: Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy. Clin. Immunol. 2002; 109: 1001-1004
• de Gracia J., Vendrell M., Alvarez A., et al.: Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int. Immunopharmacol. 2004; 4: 745-753
• Baumann U., Miescher S., Vonarburg C.: Immunoglobulin replacement therapy in antibody deficiency syndromes: are we really doing enough? Clin. Exp. Immunol. 2014; 178: 83-85S
• Orange JS., Grossman WJ., Navickis RJ., Wilkes MM.: Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin. Immunol. 2010; 137: 21-30
• Bonagura VR.: Dose and outcomes in primary immunodeficiency disorders. Clin. Exp. Immunol. 2014; 178:7-9S
• Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H.: Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy. Clin. Immunol. 2010; 125: 1354-1360
• Shapiro RS.: Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013; 111:51-55
• Wasserman RL.: Overview of recombinant human hyaluronidasefacilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 2014; 6: 553-567
• Wasserman RL., Melamed I., Stein MR., et al.: Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy. Clin. Immunol 2012; 130: 951-7 e11
• IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. Clin Exp Immunol. 1983; 52: 417-422
• Hogy B., Keinecke HO., Borte M.: Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur. J. Health. Econ. 2005; 6: 24-29
• Martin A., Lavoie L., Goetghebeur M., Schellenberg R.: Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus. Med. 2013; 23: 55-60
• Beauté J., Levy P., Millet V., et al.: Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin. Exp. Immunol. 2010; 160: 240-245
• Igarashi A., Kanegane H., Kobayashi M., Miyawaki T., Tsutani K.: Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin Ther. 2014; 36:1616-1624
• IPOPI PID Patient Needs & Outlooks Survey; Available from: http://www.ipopi.org/uploads/IPOPI PID Patient Survey - Shortened Report - 030812_Final IPOPI format.pdf; [Accesssed: 31.01.2015]
• Available from: www.mz.gov.pl; [Accessed:31.01.2015]

Identyfikatory

DOI

10.7365/JHPOR.2014.2.5